FY2029 Earnings Estimate for ITOS Issued By HC Wainwright

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a note issued to investors on Thursday, March 6th. HC Wainwright analyst S. Ramakanth anticipates that the company will earn $1.19 per share for the year. HC Wainwright has a “Buy” rating and a $46.00 price target on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share.

Several other brokerages have also recently weighed in on ITOS. Wells Fargo & Company lowered their target price on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday. JPMorgan Chase & Co. reduced their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, Wedbush restated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday.

iTeos Therapeutics Trading Down 0.6 %

Shares of NASDAQ ITOS opened at $7.05 on Friday. The stock has a market cap of $257.56 million, a PE ratio of -2.24 and a beta of 1.38. iTeos Therapeutics has a 12-month low of $6.67 and a 12-month high of $18.75. The company has a 50-day moving average of $7.52 and a 200 day moving average of $9.48.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13.

Institutional Trading of iTeos Therapeutics

Several hedge funds have recently made changes to their positions in the company. Point72 DIFC Ltd purchased a new stake in shares of iTeos Therapeutics during the 3rd quarter valued at approximately $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in iTeos Therapeutics during the fourth quarter worth $42,000. Virtus ETF Advisers LLC raised its position in iTeos Therapeutics by 58.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after purchasing an additional 3,293 shares during the period. Virtu Financial LLC acquired a new position in shares of iTeos Therapeutics in the 3rd quarter valued at $102,000. Finally, Quest Partners LLC grew its holdings in shares of iTeos Therapeutics by 914.7% during the 3rd quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after purchasing an additional 9,934 shares during the period. Hedge funds and other institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.